Dihydrostreptomycin

Summary

Dihydrostreptomycin (CHEMBL1950576) is an approved small molecule (ATC S01AA15); indicated across 1 condition including eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01AA15
• Indications: 1 condition
• Chemistry: 583.6 Da · C21H41N7O12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1950576
Name	Dihydrostreptomycin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	439369
ChEBI	CHEBI:38291
ATC	S01AA15
Molecular formula	C21H41N7O12
Molecular weight	583.6
InChIKey	ASXBYYWOLISCLQ-HZYVHMACSA-N

SMILES: C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(CO)O

IUPAC name: 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine

Also known as: Abiocine, Dihidroestreptomicina, Dihydrostreptomycin, Dihydrostreptomycine, Streptomycin, dihydro-, Vibriomycin, DIHYDROSTREPTOMYCINE, DIHYDROSTREPTOMYCIN, dihydrostreptomycin

Parent form; salt/anhydrous children: CHEMBL3188576

Patent coverage: 1,252 distinct patent families (4,187 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,058 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye infectious disorder	4	MONDO:0043885	EFO:1001888

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).